RT Journal Article
SR Electronic
T1 Analysis of common glucocorticoid response genes in childhood acute lymphoblastic leukemia in vivo identifies cell cycle but not apoptosis genes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.11.20148890
DO 10.1101/2020.07.11.20148890
A1 Aneichyk, Tatsiana
A1 Schmidt, Stefan
A1 Bindreither, Daniel
A1 Kroesbacher, Armin
A1 Mueller, Nikola S
A1 Meister, Bernhard
A1 Crazzolara, Roman
A1 Mann, Georg
A1 Panzer-Gruemayer, Renate
A1 Kofler, Reinhard
A1 Rainer, Johannes
A1 Geley, Stephan
YR 2020
UL http://medrxiv.org/content/early/2020/07/20/2020.07.11.20148890.abstract
AB Glucocorticoids (GCs) are an essential component of acute lymphoblastic leukemia (ALL) therapy. To identify genes mediating the anti-leukemic GC effects in vivo, we performed gene expression profiling of lymphoblasts from 46 children during the first 6-24h of systemic GC mono-therapy. Differential gene expression analysis across all patients revealed a considerable number of GC-regulated genes (190 induced, 179 repressed at 24h). However, when 4 leukemia subtypes (T-ALL, ETV6-RUNX1+, hyperdiploid, other preB-ALLs) were analyzed individually only 17 genes were regulated in all of them showing subtype-specificity of the transcriptional response. “Cell cycle-related” genes were down-regulated in the majority of patients, while no common changes in apoptosis genes could be identified. Surprisingly, none of the cell cycle or apoptosis genes correlated well with the reduction of peripheral blasts used as parameter for treatment response. These data suggest that (a) GC effects on cell cycle are independent of the cell death response and (b) GC-induced cell death cannot be explained by a single transcriptional pathway conserved in all subtypes. To unravel more complex, potentially novel pathways, we employed machine learning algorithms using an iterative elastic net approach, which identified gene expression signatures that correlated with the clinical response.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Austrian Science Fund (SFB021 and W1101-P13 and P6) and a grant from the Cancer Aid Society Tirol. The Tyrolean Cancer Research Institute is supported by the Tirol Kliniken GmbH and the Tyrolean Cancer Aid Society.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approved by the Ethics Committee of Innsbruck Medical University (EK1-1193-172/35) with written informed consent obtained from parents or custodiansAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw and preprocessed expression data has been deposited at the Gene Expression Omnibus (Accession number: GSE73578); during review process the data is accessible using the link: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=sfktcoyghzavrup&acc=GSE73578. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=sfktcoyghzavrup&acc=GSE73578.